Standard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS)
includes hypomethylating agents, such as azacitidine (AZA). However, the only approach …

The choice between an older matched sibling donor (MSD) and a younger matched
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …

For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell
transplantation (HCT) provides the best chance of long-term survival. A formal comparison …

BACKGROUND The development of newer strategies to improve outcomes for older
patients with secondary acute myeloid leukemia (s‐AML) is a critical unmet need …

Abstract The European Society for Blood and Marrow Transplant Research data set was
used to retrospectively analyze the outcomes of hypomethylating therapy (HMA) compared …

Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions
in a number of patients with advanced hematologic malignancies. Little is known about the …

Hematopoietic cell transplantation (HCT) provides a life-prolonging or potentially curative
treatment option for patients with hematologic malignancies. Given the high transplant …

Allografting from HLA-haploidentical donors (HID) is being increasingly utilized worldwide
for patients lacking a conventional matched donor. However, its efficacy in older patients …

As in younger patients, allogeneic stem cell transplantation (alloHSCT) offers the best
chance for durable remission in older patients (≥ 60 years) with acute myeloid leukemia …

There is a major unmet medical need for treatment options in elderly patients with acute
myeloid leukemia (AML) who are deemed ineligible for intensive treatment. The recent …